MarginsXMarginsX
Home › Markets › Health Care › NATR

Nature's Sunshine Products Inc. (NATR)

NATR trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.

Price · November 16, 2026
$10.56
+1.93% on the day
Market cap
$183.0M
Micro cap
Revenue · 2025
$480.1M
+5.7% on 2024
Net income · 2025
$19.5M
4.1% net margin

Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/275053/000162828026016540/0001628280-26-016540-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.

Profile

FieldValue
TickerNATR on Nasdaq
SectorHealth Care
IndustryBiotechnology: Pharmaceutical Preparations
CountryUnited States
IPO yearNot reported by the screener
SEC CIK0000275053
SEC industry codePharmaceutical Preparations
Incorporated inUT

Financials · 2025

LineValue
Revenue$480.1M
Net income$19.5M
Operating income$24.7M
Net margin4.1%
Operating margin5.2%
Revenue growth+5.7%
Cash$93.9M
Total assets$261.1M
P/E (computed)9.4×
P/S (computed)0.4×

Warning signs

Cash runway
Cash-flow positive
$89.4M cash at September 30, 2026
Share count, 1 year
-1.0%
2025-10-24 to 2026-10-23 · -9.2% over 3 years
Going-concern doubt
No
10-Q filed November 4, 2026
Insider net buying, 12 months
$518K
Through September 30, 2026
SignFindingSource
Going concernNo going-concern finding.10-Q 2026-11-04
Cash and burn$89.4M cash; operating cash flow $4.9M a quarter.Report 2026-09-30
Shares outstanding17,328,776 (2026-10-23); 17,495,563 a year earlier; 19,075,041 three years earlier.Cover page 2026-10-23
Reverse splits, 3 yearsNone foundNone on EDGAR
Shelf and offerings, 12 months0 S-3/F-3 shelf filings; 0 424B5 takedownsNone on EDGAR
Exchange deficiency notices, 12 monthsNoneNone on EDGAR
AuditorDeloitte & Touche LLP, Salt Lake City, Utah, United StatesPCAOB Form AP 2026-03-30
Late filings, 12 monthsNoneNone on EDGAR
Insider trades, 12 monthsBought $2.6M, sold $2.1M on the open marketSEC Forms 3/4/5 data sets 2026-09-30

From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.

Quarterly results

QuarterRevenueNet incomeOp. cash flowCashTotal debtTTM revenueSource
Q3 2026
2026-09-30
$116.6M$1.9M$10.8M$89.4MNo debt tags$480.3M10-Q 2026-11-04
Q2 2026
2026-06-30
$117.0M$3.5M$835K$82.5MNo debt tags$492.0M10-Q 2026-08-06
Q1 2026
2026-03-31
$122.9M$5.1M-$1.8M$87.6MNo debt tags$489.8M10-Q 2026-05-07
Q4 2025
2025-12-31
$123.8M$4.1M$9.9M$93.9MNo debt tags$480.1M10-K 2026-03-10
Q3 2025
2025-09-30
$128.3M$5.3M$18.5M$95.6MNo debt tags$474.5M10-Q 2026-11-04
Q2 2025
2025-06-30
$114.8M$5.3M$4.3M$81.3MNo debt tags$460.8M10-Q 2026-08-06
Q1 2025
2025-03-31
$113.2M$4.7M$2.6M$86.5MNo debt tags$456.6M10-Q 2026-05-07
Q4 2024
2024-12-31
$118.2M-$321K$12.2M$84.7MNo debt tags$454.4M10-K 2026-03-10

From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).

Key SEC documents

DocumentFormFiled
Latest prospectus or offering document424B52025-06-27
Latest annual report10-K2026-03-10
Latest quarterly / interim10-Q2026-11-04
Latest current report8-K2026-11-04
Latest proxyDEFA14A2026-04-20

Source: SEC EDGAR submissions feed, 1,000 recent filings. All filings on EDGAR.

Price moves

WindowReturn
1 week-4.7%
1 month-18.8%
3 months-32.3%
Year to date-52.0%
1 year-50.0%
From 52-week high-62.7%

Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.

Peers in Biotechnology: Pharmaceutical Preparations

TickerCompanyPriceDayMarket cap
RNACCartesian Therapeutics Inc.$6.08-4.25%$185.5M
SLGLSol-Gel Technologies Ltd.$54.96-0.29%$179.9M
WHWKWhitehawk Therapeutics Inc.$3.01-1.63%$177.6M
KRROKorro Bio Inc.$12.71-6.61%$174.5M
IFRXInflaRx N.V.$1.18+0.85%$173.9M
TRDAEntrada Therapeutics Inc.$5.00-1.77%$195.8M
NGENNervGen Pharma Corp.$1.82-3.19%$195.9M
KROSKeros Therapeutics Inc.$10.03-2.62%$196.8M

The full dossier has every filing, three years of financials, private raises and the people who signed them.

Open the full dossier